Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528853 | 0.91 | MAPT (0.75) | KDM4EALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL528045 | 0.90 | MAPT (0.61) | KDM4EALDH1A1MAPTLMNAGAA | |
| SCHEMBL528865 | 0.90 | ALDH1A1 (0.54) | KDM4EALDH1A1MAPTLMNAGAA | |
| SCHEMBL528515 | 0.88 | ALDH1A1 (0.52) | KDM4EALDH1A1MAPTLMNAGAA | |
| SCHEMBL528291 | 0.87 | KDM4E (0.68) | KDM4EALDH1A1MAPTLMNAHPGD | |
| SCHEMBL529361 | 0.86 | ALDH1A1 (0.50) | KDM4EALDH1A1MAPTLMNAGAA | |
| SCHEMBL528613 | 0.84 | MAPT (0.54) | KDM4EALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL528294 | 0.83 | KDM4E (0.65) | KDM4EALDH1A1MAPTLMNAGAA | |
| SCHEMBL528306 | 0.83 | KDM4E (0.67) | KDM4EALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL529003 | 0.82 | MAPT (0.66) | KDM4EALDH1A1MAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012014127-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |